drugset / Trial / NCT00945880

Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive

NCT00945880 ↗

Phase 1 Completed 12 enrolled Eiger BioPharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the hypothesis that clemizole hydrochloride is safe and well tolerated when administered to subjects who are infected with hepatitis C virus and have not yet received treatment. This study will also examine how the virus and body respond to clemizole hydrochloride.

Timeline

Start
2009-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Clemizole Small molecule 100 mg Oral